Literature DB >> 25921114

Nedaplatin salvage chemotherapy for cervical cancer.

Wu-Ju Li1, Jia-Ying Jiang, Xian-Lian Wang.   

Abstract

PURPOSE: This systematic analysis was conducted to evaluate the efficacy and safety of nedaplatin based salvage chemotherapy for treatment of patients with advanced cervical cancer.
METHODS: Clinical studies evaluating the efficacy and safety of nedaplatin based regimens on response and safety for patients with cervical cancer were identified using a predefined search strategy. Pooled response rates (RRs) were calculated.
RESULTS: For nedaplatin based regimens, 5 clinical studies including 264 patients with advanced cervical cancer were considered eligible for inclusion. The analysis showed that, in all patients, pooled RR was 74.6% (197/264). Major adverse effects were leukopenia, thrombocytopenia and nausea/vomiting. No treatment related death occurred with nedaplatin based treatment.
CONCLUSION: This systematic analysis suggests that nedaplatin based regimens are associated with good activity with acceptable tolerability in treating patients with advanced cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25921114     DOI: 10.7314/apjcp.2015.16.8.3159

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  3 in total

1.  MicroRNA-27b up-regulated by human papillomavirus 16 E7 promotes proliferation and suppresses apoptosis by targeting polo-like kinase2 in cervical cancer.

Authors:  Fei Liu; Shimeng Zhang; Zhen Zhao; Xinru Mao; Jinlan Huang; Zixian Wu; Lei Zheng; Qian Wang
Journal:  Oncotarget       Date:  2016-04-12

2.  Elevated MYO10 Predicts Poor Prognosis and its Deletion Hampers Proliferation and Migration Potentials of Cells Through Rewiring PI3K/Akt Signaling in Cervical Cancer.

Authors:  Jian-Hui He; Jian-Guo Chen; Bin Zhang; Jing Chen; Ke-Li You; Jie-Mei Hu; Jia-Wen Xu; Le Chen
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

3.  Suppression of miR-22, a tumor suppressor in cervical cancer, by human papillomavirus 16 E6 via a p53/miR-22/HDAC6 pathway.

Authors:  Weerayut Wongjampa; Tipaya Ekalaksananan; Peechanika Chopjitt; Jureeporn Chuerduangphui; Pilaiwan Kleebkaow; Natcha Patarapadungkit; Chamsai Pientong
Journal:  PLoS One       Date:  2018-10-31       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.